On 12 December 2016, orphan designation (EU/3/16/1799) was granted by the European Commission to Albany Regulatory Consulting Ltd, United Kingdom, for cabiralizumab for the treatment of tenosynovial giant cell tumour, localised and diffuse type.
The sponsorship was transferred to TMC Pharma Services Ltd, United Kingdom, in November 2017.
The sponsorship was transferred to TMC Pharma (EU) Limited, Ireland in November 2019.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in July 2020 on request of the Sponsor.
Treatment of tenosynovial giant cell tumour, localised and diffuse type
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: